In patients with venous thromboembolism and cancer, a low-molecular-weight heparin may be safer than an oral anticoagulant.
This was the conclusion of Dr. Guy Meyer, of the Department of Respiratory and Critical Care Medicine, Hôpital Européen Georges Pompidou, Paris V University, Paris, France, and colleagues.
Warfarin sodium used for treating venous thromboembolism in cancer patients is known to be associated with a significant risk of recurrence and bleeding.
The investigators conducted a randomised, open-label multicentre study involving 146 patients with venous thromboembolism and cancer.
They compared the low-molecular-weight heparin enoxaparin sodium (1.5mg/kg once a day) given subcutaneously with warfarin given for three months. A total of 138 patients could be evaluated (71 in the warfarin group and 67 in the enoxaparin group).
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!